GlassScriptPhysician profile
James H Shero
NPI 1114951662
$733.37
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $58.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $293.87 | 2019-2020 | |
| Novo Nordisk INC | $226.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.22 | 2019 | |
| Astellas Pharma US INC | $40.84 | 2019 | |
| Merck Sharp & Dohme LLC | $26.35 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.09 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.76 | 2019 | |
| Amgen INC. | $15.04 | 2019 | |
| Amarin Pharma, INC. | $13.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.25 | 2019 | |
| Pfizer INC. | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.